Cystic fibrosis is an inherited disease caused by mutations in a single gene that controls the movement of salt and water across cell surfaces throughout the body. Because this channel protein malfunctions, mucus in the lungs, digestive tract, and other organs becomes abnormally thick and sticky, leading to chronic infections, poor nutrient absorption, and progressive organ damage. It is the most common life-shortening genetic disease among people of European descent, occurring in roughly 1 in 2,500 live births in that population, though it appears in every ethnic group.
What Goes Wrong at the Cellular Level
The gene at the center of cystic fibrosis is called CFTR, short for cystic fibrosis transmembrane conductance regulator. It was identified in 1989, and its protein product sits on the surface of epithelial cells, the cells that line your airways, gut, sweat glands, and reproductive organs. The CFTR protein works as an ion channel, meaning it lets chloride and bicarbonate ions pass through the cell membrane.1PubMed. Genetics of cystic fibrosis: CFTR mutation classifications toward genotype-based CF therapies When CFTR doesn’t work, chloride stays trapped inside cells, and water that would normally follow the chloride out onto the surface stays put too. The result is a thin, watery layer on those surfaces that should be there to keep things moving, but instead dries out and leaves behind dense, sticky mucus.
The channel also conducts bicarbonate, though at a lower rate than chloride.2Journal of Cystic Fibrosis. Mechanism of direct bicarbonate transport by the CFTR anion channel Bicarbonate helps regulate the acidity and physical properties of secretions. When both chloride and bicarbonate transport fail, and sodium absorption through a separate channel ramps up to compensate, the fluid balance at the cell surface tips dramatically. That imbalance is the root cause of nearly every symptom in cystic fibrosis.3PubMed Central. Mucus, mucins, and cystic fibrosis
More Than 1,900 Mutations, but One Dominates
Cystic fibrosis is autosomal recessive, which means you need two faulty copies of the CFTR gene to develop the disease, one inherited from each parent. Carriers who have just one faulty copy typically have no symptoms. Researchers have catalogued more than 1,900 distinct mutations in the CFTR gene, grouped into classes based on what they do to the protein. Some mutations stop the protein from being made at all. Others let it get made but fold it incorrectly so the cell destroys it before it reaches the surface. Still others produce a channel that reaches the surface but doesn’t open properly or doesn’t stay open long enough.
One mutation dwarfs the rest in frequency: F508del, a deletion of a single amino acid. Across Europe, roughly 80% or more of patients carry at least one copy of this mutation, which causes the protein to misfold and get degraded before it ever reaches the cell surface.4Journal of Cystic Fibrosis. Spectrum of CFTR mutations in European patients with cystic fibrosis Because different mutations cause different degrees of channel dysfunction, the severity of the disease can vary considerably from person to person, even among siblings who share the same mutations.
Which Organs Are Affected
The thick mucus caused by CFTR dysfunction accumulates in the lungs, gastrointestinal tract, and pancreatic ducts most prominently, but the disease touches nearly every organ system that relies on fluid secretion.5PubMed Central. Mucus, mucins, and cystic fibrosis
- Lungs: Thick mucus clogs the airways and creates an environment where bacteria thrive, leading to chronic infections and progressive lung damage. This is the leading cause of illness and death in CF.
- Pancreas: Mucus blocks the ducts that deliver digestive enzymes to the small intestine. Without those enzymes, fats and proteins pass through undigested, causing malnutrition and greasy, bulky stools. Most people with CF need to take enzyme capsules with every meal.
- Liver: Bile ducts can become obstructed, leading to a pattern of liver scarring called focal biliary fibrosis. This is usually silent, but in about 10% of cases it progresses to portal hypertension, a dangerous buildup of pressure in the liver’s blood vessels that can eventually require transplantation.6Journal of Hepatology. Hepatic manifestations of cystic fibrosis
- Sweat glands: CFTR normally reabsorbs salt from sweat as it travels up the sweat duct. Without a working channel, chloride stays in the sweat and, because of electrical charge balance, sodium stays too. The result is noticeably salty sweat, which is so characteristic that it forms the basis of the main diagnostic test.7Cell. Loss of CFTR Chloride Channels Alters Salt Absorption by Cystic Fibrosis Airway Epithelia In Vitro
- Reproductive system: Nearly all men with CF are infertile because the vas deferens, the tubes that carry sperm, fail to develop properly during fetal life. Estimates range from about 95% to 98% of affected males.8PubMed Central. Congenital bilateral absence of the vas deferens as an atypical form of cystic fibrosis: reproductive implications and genetic counseling9Journal of Clinical & Translational Endocrinology. Testicular function and fertility outcomes in males with CF Women with CF can conceive naturally, though thickened cervical mucus may reduce fertility.
Lung Infections Follow a Pattern
The airway mucus in CF does more than obstruct airflow. It weakens the lung’s built-in defense system by trapping bacteria in a sticky layer that the body’s immune cells struggle to clear. The specific bacteria that colonize the lungs tend to change over a person’s lifetime. In childhood, Staphylococcus aureus and Haemophilus influenzae are the most common species found in sputum cultures. By the second and third decades of life, Pseudomonas aeruginosa typically becomes the dominant organism.10PubMed Central. Cystic fibrosis lung environment and Pseudomonas aeruginosa infection
Pseudomonas is especially problematic because it forms biofilms, communities of bacteria encased in a protective matrix that antibiotics have difficulty penetrating. Once Pseudomonas establishes a chronic presence in the lungs, it is almost impossible to eradicate entirely. This is a major reason why aggressive early treatment and airway clearance routines are so important. The goal is to delay chronic colonization for as long as possible, since its onset is strongly linked to faster lung function decline.
How Cystic Fibrosis Is Diagnosed
Most cases are now caught through newborn screening. In the United States and many other countries, a heel-prick blood test taken within the first few days of life measures a substance called immunoreactive trypsinogen, which tends to be elevated in babies with CF because their pancreatic ducts are already blocked. If that initial result is high, the next step varies by screening program. Some protocols repeat the blood test a week or two later, while others move directly to DNA analysis looking for common CFTR mutations.11Pediatrics. Clarification of Laboratory and Clinical Variables That Influence Cystic Fibrosis Newborn Screening With Initial Analysis of Immunoreactive Trypsinogen The screening approach that pairs the blood test with DNA analysis for a panel of mutations catches more cases, with one study calculating a sensitivity above 96% for a 23-mutation panel, compared to about 80% for the blood-test-only method.12Pediatrics. Clarification of Laboratory and Clinical Variables That Influence Cystic Fibrosis Newborn Screening With Initial Analysis of Immunoreactive Trypsinogen
Regardless of what triggers the suspicion, the definitive diagnostic test is the sweat chloride test. A small area of skin, usually on the forearm, is stimulated with a chemical called pilocarpine to produce sweat, which is collected and analyzed for its chloride concentration. A chloride level above a certain threshold confirms the diagnosis.13PubMed Central. Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation This test has been the gold standard since the 1950s and remains so today, even with the availability of genetic testing, because it directly measures how well CFTR is functioning rather than simply identifying mutations whose clinical significance can sometimes be unclear.
Carrier Frequency and Why It Varies by Ancestry
Among people of European descent, about 1 in 25 are carriers of a CFTR mutation, making it one of the most common recessive genetic conditions in that population.14BioMed Research International. Characterization of Ancestral Origin of Cystic Fibrosis of Patients with New Reported Mutations in CFTR CF occurs in all racial and ethnic groups, but at lower rates in people of African, Asian, and Hispanic descent. The F508del mutation is estimated to have originated somewhere between 11,000 and 34,000 years ago in Europe, then spread across the continent.15BioMed Research International. Characterization of Ancestral Origin of Cystic Fibrosis of Patients with New Reported Mutations in CFTR
That high carrier frequency has puzzled geneticists for decades. A mutation that causes serious disease in people who inherit two copies should, over time, become rarer as affected individuals have fewer children. The fact that it has stayed so common suggests that carrying one copy may have conferred some survival advantage. The leading hypothesis is that CF carriers had better resistance to infectious diarrheal diseases caused by organisms like Vibrio cholerae (cholera) and certain strains of E. coli, because their intestinal chloride secretion may be slightly reduced, limiting the fluid loss that makes those illnesses deadly.16PubMed Central. Active intestinal chloride secretion in human carriers of cystic fibrosis mutations: an evaluation of the hypothesis that heterozygotes have subnormal active intestinal chloride secretion Resistance to typhoid fever has also been proposed as a selective factor.17PubMed Central. Evaluating candidate agents of selective pressure for cystic fibrosis The evidence is suggestive but not definitive, and the true explanation may involve multiple pressures or genetic drift.
CFTR Modulator Therapy
For most of its history, CF treatment focused entirely on managing symptoms: clearing mucus from the lungs with chest physiotherapy, fighting infections with antibiotics, and replacing missing digestive enzymes. Those treatments are still essential, but since 2012, a new class of drugs has changed the trajectory of the disease. Called CFTR modulators, these small molecules target the underlying protein defect rather than its downstream consequences.
The most significant breakthrough has been elexacaftor-tezacaftor-ivacaftor, a triple-combination therapy approved in 2019 that pairs two “correctors” (drugs that help the misfolded protein reach the cell surface) with a “potentiator” (a drug that helps the channel open once it gets there).18PubMed Central. Elexacaftor-Tezacaftor-Ivacaftor: The First Triple-Combination Cystic Fibrosis Transmembrane Conductance Regulator Modulating Therapy For patients with at least one copy of F508del, which covers the majority of the CF population, the clinical improvements have been dramatic: lung function gains of 10 to 14 percentage points on average, fewer lung infections, reduced hospitalizations, and meaningful weight gain. Laboratory studies have shown the combination can also rescue several rarer folding mutations beyond F508del, reaching therapeutically meaningful levels of protein correction.19PubMed Central. Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination
The limitations are real, though. Modulators do not work for every mutation. People with certain “nonsense” mutations, where the gene contains a premature stop signal that prevents any protein from being made, produce no CFTR protein at all, meaning there is nothing for a corrector or potentiator to act on. Those patients, roughly 10% of the CF population, still have no targeted therapy available and continue to rely on traditional symptom management.
Life Expectancy and How It Has Changed
In the 1950s, most children with cystic fibrosis did not survive past early childhood. By 2010, projected median survival for a child born and diagnosed that year had reached about 37 years for females and 40 years for males, assuming mortality rates held steady at 2010 levels. If the rate of improvement seen between 2000 and 2010 continued, projected survival exceeded 50 years.20PubMed Central. Longevity of patients with cystic fibrosis in 2000 to 2010 and beyond: survival analysis of the Cystic Fibrosis Foundation patient registry The widespread adoption of CFTR modulators since 2019 is expected to push those numbers higher still, though it will take years of follow-up data to confirm new projections.
Living longer with CF brings its own set of challenges. Conditions that were once rare because patients didn’t live long enough to develop them are now part of routine care. CF-related diabetes, driven by progressive damage to the insulin-producing cells in the pancreas, eventually affects a large share of adults with the disease. Bone thinning from chronic inflammation and poor nutrient absorption becomes a concern. And as the earlier section noted, liver disease may slowly progress over decades.
Mental Health and Treatment Burden
The daily treatment regimen for cystic fibrosis is intensive. Even with modulators, most people still spend one to two hours a day on chest physiotherapy, nebulized medications, and enzyme management. The cumulative weight of this routine, layered on top of frequent clinic visits, periodic hospitalizations, and the psychological stress of managing a chronic illness, takes a measurable toll. Studies have found high rates of both depression and anxiety in people with CF and in their parent caregivers. Those psychological symptoms are not just quality-of-life concerns: they have been linked to worse lung function, lower body weight, poorer adherence to treatment, more frequent hospitalizations, and higher healthcare costs.21Thorax. International Committee on Mental Health in Cystic Fibrosis: Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus statements for screening and treating depression and anxiety
In response, the Cystic Fibrosis Foundation and the European Cystic Fibrosis Society have issued consensus guidelines recommending routine annual screening for depression and anxiety in all patients aged 12 and older, and in parent caregivers as well.22Thorax. International Committee on Mental Health in Cystic Fibrosis: Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus statements for screening and treating depression and anxiety This was a significant shift in how CF care teams think about the disease, acknowledging that mental health is not a side issue but a factor that directly influences physical outcomes.
Gene Editing and the Search for a Cure
CFTR modulators have transformed outcomes for many, but they are lifelong treatments that do not fix the underlying genetic error. The ultimate ambition in CF research is a one-time correction at the DNA level. Gene therapy, the idea of delivering a working copy of the CFTR gene into airway cells, has been pursued since the early 1990s with limited success. The lung is a particularly difficult target because its natural defenses, the same mucus layer and immune responses that are supposed to keep foreign material out, also block therapeutic gene delivery vehicles.
More recent interest has shifted toward gene editing tools, especially CRISPR-based systems, which could in theory correct the mutation in a patient’s own cells rather than adding an extra gene copy.23PubMed Central. Genome Editing for Cystic Fibrosis The appeal of editing over traditional gene therapy is precision: rather than inserting a whole new gene that may not integrate in the right spot or may be silenced over time, editing aims to fix the exact mutation in its natural chromosomal context. Proof-of-concept work in cell cultures and organoids has been encouraging. The harder problems are delivery, getting the editing machinery into enough of the right cells deep in the lungs to make a clinical difference, and durability, since airway surface cells turn over regularly and would need to be re-edited unless the correction reaches the stem cells that replenish them. Clinical trials remain in early stages, and a practical gene-editing cure is likely still years away. For the roughly 10% of patients whose mutations cannot be addressed by current modulators, this line of research represents the most promising long-term hope.